Distinguished in Membranous Nephropathy

Loreto Gesualdo

11 G. Cesare Square, 
Bari, IT 
Distinguished in Membranous Nephropathy
11 G. Cesare Square, 
Bari, IT 
OverviewLocationsClinical Research

Overview

Loreto Gesualdo practices in Bari, Italy. Mr. Gesualdo is rated as a Distinguished expert by MediFind in the treatment of Membranous Nephropathy. His top areas of expertise are Glomerulonephritis, IgA Nephropathy, Diabetic Nephropathy, Kidney Transplant, and Nephrectomy.

His clinical research consists of co-authoring 470 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles in the study of Membranous Nephropathy.

Gender
Male

Locations

11 G. Cesare Square, Bari, 70124, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
Enrollment Status: Completed
Publish Date: April 02, 2024
Intervention Type: Drug
Study Drugs: Daprodustat, Darbepoetin Alpha
Study Phase: Phase 3
Approccio Innovativo di Trapianto di Microbiota Fecale Applicato Alla Malattia Renale Cronica
Approccio Innovativo di Trapianto di Microbiota Fecale Applicato Alla Malattia Renale Cronica
Enrollment Status: Completed
Publish Date: February 08, 2023
A 52-week Open-label (Sponsor-blind), Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of Daprodustat Compared to Recombinant Human Erythropoietin in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Initiating Dialysis
A 52-week Open-label (Sponsor-blind), Randomized, Active-controlled, Parallel-group, Multi-center Study to Evaluate the Efficacy and Safety of Daprodustat Compared to Recombinant Human Erythropoietin in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Initiating Dialysis
Enrollment Status: Completed
Publish Date: October 20, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

470 Total Publications

Author Correction: Exome analysis links kidney malformations to developmental disorders and reveals causal genes.
Author Correction: Exome analysis links kidney malformations to developmental disorders and reveals causal genes.
Journal: Nature communications
Published: October 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Gesualdo's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 16 Advanced Conditions
View All 65 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile